Last reviewed 2026-04-23 · How we verify

Cerdulatinib 0.37% gel

Dermavant Sciences GmbH · Phase 2 active Small molecule

Cerdulatinib 0.37% gel is a JAK1/SYK inhibitor Small molecule drug developed by Dermavant Sciences GmbH. It is currently in Phase 2 development for Atopic dermatitis (topical), Alopecia areata (topical). Also known as: DMVT-502.

Cerdulatinib is a dual JAK1/SYK inhibitor that suppresses inflammatory signaling pathways in immune cells to reduce skin inflammation.

Cerdulatinib is a dual JAK1/SYK inhibitor that suppresses inflammatory signaling pathways in immune cells to reduce skin inflammation. Used for Atopic dermatitis (topical), Alopecia areata (topical).

At a glance

Generic name	Cerdulatinib 0.37% gel
Also known as	DMVT-502
Sponsor	Dermavant Sciences GmbH
Drug class	JAK1/SYK inhibitor
Target	JAK1, SYK
Modality	Small molecule
Therapeutic area	Dermatology/Immunology
Phase	Phase 2

Mechanism of action

Cerdulatinib inhibits both Janus kinase 1 (JAK1) and spleen tyrosine kinase (SYK), which are key enzymes in the signaling cascades that drive T-cell and B-cell activation and inflammatory cytokine production. By blocking these kinases, the drug reduces the pathogenic immune response in inflammatory skin conditions. The topical gel formulation allows direct application to affected skin areas while minimizing systemic exposure.

Approved indications

Atopic dermatitis (topical)
Alopecia areata (topical)

Common side effects

Application site irritation
Application site erythema
Pruritus

Key clinical trials

Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cerdulatinib 0.37% gel CI brief — competitive landscape report
Cerdulatinib 0.37% gel updates RSS · CI watch RSS
Dermavant Sciences GmbH portfolio CI

Frequently asked questions about Cerdulatinib 0.37% gel

What is Cerdulatinib 0.37% gel?

Cerdulatinib 0.37% gel is a JAK1/SYK inhibitor drug developed by Dermavant Sciences GmbH, indicated for Atopic dermatitis (topical), Alopecia areata (topical).

How does Cerdulatinib 0.37% gel work?

Cerdulatinib is a dual JAK1/SYK inhibitor that suppresses inflammatory signaling pathways in immune cells to reduce skin inflammation.

What is Cerdulatinib 0.37% gel used for?

Cerdulatinib 0.37% gel is indicated for Atopic dermatitis (topical), Alopecia areata (topical).

Who makes Cerdulatinib 0.37% gel?

Cerdulatinib 0.37% gel is developed by Dermavant Sciences GmbH (see full Dermavant Sciences GmbH pipeline at /company/dermavant-sciences-gmbh).

Is Cerdulatinib 0.37% gel also known as anything else?

Cerdulatinib 0.37% gel is also known as DMVT-502.

What drug class is Cerdulatinib 0.37% gel in?

Cerdulatinib 0.37% gel belongs to the JAK1/SYK inhibitor class. See all JAK1/SYK inhibitor drugs at /class/jak1-syk-inhibitor.

What development phase is Cerdulatinib 0.37% gel in?

Cerdulatinib 0.37% gel is in Phase 2.

What are the side effects of Cerdulatinib 0.37% gel?

Common side effects of Cerdulatinib 0.37% gel include Application site irritation, Application site erythema, Pruritus.

What does Cerdulatinib 0.37% gel target?

Cerdulatinib 0.37% gel targets JAK1, SYK and is a JAK1/SYK inhibitor.

Drug class: All JAK1/SYK inhibitor drugs
Target: All drugs targeting JAK1, SYK
Manufacturer: Dermavant Sciences GmbH — full pipeline
Therapeutic area: All drugs in Dermatology/Immunology
Indication: Drugs for Atopic dermatitis (topical)
Indication: Drugs for Alopecia areata (topical)
Also known as: DMVT-502
Compare: Cerdulatinib 0.37% gel vs similar drugs
Pricing: Cerdulatinib 0.37% gel cost, discount & access